RxDoctor Payments Data

Maria Delgado Lelievre, MD

Internal Medicine · Miami, FLNPI 1477728723

Payments from drug & device makers

$80,251in general payments, 2019–2025

Across 124 payments — averaging $647.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$75K
  • AstraZeneca$2K
  • Abbott$2K
  • Recor Medical Inc$446
  • Heartflow, Inc.$149
  • Ablative Solutions, Inc.$121
  • plus $223 from 5 others

What the payments were for

  • Consulting fees$45,58657%
  • Speaking & faculty fees$14,49418%
  • Travel & lodging$16,22320%
  • Food & beverage$3,9485%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic107$75,300
AstraZeneca3$2,012
Abbott1$2,000
Recor Medical Inc5$446
Heartflow, Inc.1$149
Ablative Solutions, Inc.1$121
Janssen Scientific Affairs, LLC1$116
Johnson & Johnson2$40
Novo Nordisk1$25
E.r. Squibb & Sons, L.L.C.1$24
Amgen1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,251 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$84,881
Medicare patients
220
Services billed
1,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$20,657
EntrestoSacubitril/Valsartan19$15,884
FarxigaDapagliflozin Propanediol15$11,780
Telmisartan51$2,486
Eplerenone18$2,267
Amlodipine Besylate296$2,093
Losartan Potassium176$1,984
Nifedipine ErNifedipine39$1,369
Rosuvastatin Calcium58$1,139
Spironolactone75$860
Isosorbide Dinitrate16$706
Atorvastatin Calcium55$697
Ezetimibe34$675
Metoprolol Succinate53$652
Indapamide62$618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$2,012$11,78015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →